Alogliptin And Metformin Hydrochloride Tablet, Film Coated
NDC Package 11532-1255-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Alogliptin And Metformin Hydrochloride tablets is a drug for further processing. This formulation utilizes a tablet, film coated delivery system. Marketed by Takeda Pharmaceuticals Co Ltd, this product is identified by NDC 11532-1255.

Identification & Billing

NDC Package Code
11532-1255-1
Package Description
26000 TABLET, FILM COATED in 1 DRUM
Product Code
11532-1255
11-Digit Billing Format
11532125501

Clinical Specifications

Proprietary Name
Alogliptin And Metformin Hydrochloride
Non-Proprietary Name
Alogliptin And Metformin Hydrochloride
Substance Name
Alogliptin Benzoate; Metformin Hydrochloride
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Active Ingredient(s)

Regulatory & Marketing

Labeler Name
Takeda Pharmaceuticals Co Ltd
Product Type
Drug For Further Processing
Marketing Category
DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
Start Marketing Date
02-05-2013
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 11532-1255-1 identifies a specific commercial package of 26000 tablet, film coated in 1 drum of Alogliptin And Metformin Hydrochloride (UNFINISHED drug), drug for further processing labeled by Takeda Pharmaceuticals Co Ltd. This tablet, film coated is formulated for use and contains alogliptin benzoate; metformin hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Takeda Pharmaceuticals Co Ltd on February 05, 2013. The current certification is valid through December 31, 2026.

How is this Takeda Pharmaceuticals Co Ltd product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 11532125501. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
11532-1255-1
11-Digit CMS (5-4-2)
11532-1255-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.